Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.

• Male or female study participants aged 18 to 60 years (inclusive) at screening.

• Diagnosis of multiple sclerosis (MS) according to the 2017 Revised McDonald criteria (Thompson et al 2018). Relapsing forms of MS: relapsing-remitting MS (RRMS), oractive secondary progressive MS (SPMS).

Exclusion Criteria:

• Participants suspected of not being able or willing to cooperate or comply withstudy protocol requirements in the opinion of the Investigator or emergence of anyclinically significant condition/disease (e.g. active systemic bacterial, viral orfungal infections) during screening prior to Day 1 which might result in safety riskfor participants.

• Participants with history of confirmed progressive multifocal leukoencephalopathy (PML) or neurological symptoms consistent with PML.

• Participants at risk of developing or having reactivation of hepatitis

• Emergence of active chronic disease (or stable but treated with immune therapy)prior to Day 1 of the immune system other than MS (e.g. rheumatoid arthritis,scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or withimmunodeficiency syndrome (hereditary immune deficiency, drug-induced immunedeficiency).

• Pregnant or nursing (lactating) women

• History of lymphoproliferative disease or any known malignancy or history ofmalignancy of any organ system (except for basal cell carcinoma, or squamous cellcarcinomas of the skin that have been treated with no evidence of recurrence in thepast 3 months).

• Participants taking prohibited therapies, including B cell targeted therapies (e.g.such as ocrelizumab, rituximab, ofatumumab, ublituximab, and inebilizumab)

Other protocol-defined inclusion/exclusion criteria may apply